Unveiling the Clinical Benefits of High-Volume Hemodiafiltration: Optimizing the Removal of Medium-Weight Uremic Toxins and Beyond
Open Access
Abstract
Dialysis treatment has improved the survival of patients with kidney failure. However, the hospitalization and mortality rates remain alarmingly high, primarily due to incomplete uremic toxin elimination. High-volume hemodiafiltration (HDF) has emerged as a promising approach that significantly improves patient outcomes by effectively eliminating medium and large uremic toxins, which explains its increasing adoption, particularly in Europe and Japan. Interest in this therapy has grown following the findings of the recently published CONVINCE study, as well as the need to understand the mechanisms behind the benefits. This comprehensive review aims to enhance the scientific understanding by explaining the underlying physiological mechanisms that contribute to the positive effects of HDF in terms of short-term benefits, like hemodynamic tolerance and cardiovascular disease. Additionally, it explores the rationale behind the medium-term clinical benefits, including phosphorus removal, the modulation of inflammation and oxidative stress, anemia management, immune response modulation, nutritional effects, the mitigation of bone disorders, neuropathy relief, and amyloidosis reduction. This review also analyzes the impact of HDF on patient-reported outcomes and mortality. Considering the importance of applying personalized uremic toxin removal strategies tailored to the unique needs of each patient, high-volume HDF appears to be the most effective treatment to date for patients with renal failure. This justifies the need to prioritize its application in clinical practice, initially focusing on the groups with the greatest potential benefits and subsequently extending its use to a larger number of patients.Keywords
Funding Information
- Fresenius Medical Care Chile
This publication has 177 references indexed in Scilit:
- Effects of Hemodiafiltration and High Flux Hemodialysis on Nerve Excitability in End-Stage Kidney DiseasePLOS ONE, 2013
- Online haemodiafiltration: definition, dose quantification and safety revisitedNephrology Dialysis Transplantation, 2013
- Effect of Online Hemodiafiltration on All-Cause Mortality and Cardiovascular OutcomesJournal of the American Society of Nephrology, 2012
- Circulating EndotoxemiaClinical Journal of the American Society of Nephrology, 2011
- The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008Journal of Clinical Epidemiology, 2010
- Hemofiltration and Hemodiafiltration Reduce Intradialytic Hypotension in ESRDJournal of the American Society of Nephrology, 2010
- Aspects of Immune Dysfunction in End-stage Renal DiseaseClinical Journal of the American Society of Nephrology, 2008
- Inflammation and Oxidative Stress in Patients on HemodiafiltrationAmerican Journal of Nephrology, 2008
- Relationship between carotid intima-media thickness and arterial stiffness in children after Kawasaki diseaseArchives of Disease in Childhood, 2007
- Review on uremic toxins: Classification, concentration, and interindividual variabilityKidney International, 2003